[Kinetics of thromboxane A2 and prostacyclin during reperfusion after induced ischemia in canine hearts]. 1985

F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D013931 Thromboxanes Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase. Thromboxane
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
November 1985, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
August 1991, Prostaglandins, leukotrienes, and essential fatty acids,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
February 1988, Arzneimittel-Forschung,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
January 1987, Japanese circulation journal,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
January 1988, Sovetskaia meditsina,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
January 1982, Journal of cardiovascular pharmacology,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
July 1986, Kardiologiia,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
December 1990, Clinical and investigative medicine. Medecine clinique et experimentale,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
January 2000, Hepato-gastroenterology,
F Nomura, and H Hirose, and H Matsuda, and S Nakano, and R Shirakura, and M Ohtani, and M Kaneko, and Y Sasako, and Y Kawashima, and T Kuzuya
February 1993, Circulation research,
Copied contents to your clipboard!